Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
Details : Results showed that TLC599 (Dexamethasone Sodium Phosphate), a proprietary BioSeizer, demonstrated statistically significantly greater reduction in WOMAC pain and function as well as VAS scores compared to placebo through 24 weeks.
Product Name : TLC599
Product Type : Steroid
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
TLC and Strides partner to launch Liposomal Amphotericin B in India
Details : The partnership aims to support the TLC for the launch and commercialization of their lead product AmphoTLC (amphotericin B) in India. It will be indicated for the COVID-19-associated mucormycosis cases.
Product Name : AmphoTLC
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 19, 2021
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership